No abstract available
MeSH terms
-
Biosimilar Pharmaceuticals / administration & dosage
-
Biosimilar Pharmaceuticals / adverse effects
-
Biosimilar Pharmaceuticals / economics
-
Biosimilar Pharmaceuticals / therapeutic use
-
Diabetes Complications / economics
-
Diabetes Complications / prevention & control*
-
Diabetes Mellitus, Type 1 / blood
-
Diabetes Mellitus, Type 1 / complications
-
Diabetes Mellitus, Type 1 / drug therapy*
-
Diabetes Mellitus, Type 1 / economics
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / economics
-
Drug Administration Schedule
-
Drug Monitoring / economics
-
Drug Monitoring / trends
-
Health Care Costs / trends
-
Humans
-
Hyperglycemia / prevention & control
-
Hypoglycemia / chemically induced
-
Hypoglycemia / prevention & control
-
Hypoglycemic Agents / administration & dosage*
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / economics
-
Hypoglycemic Agents / therapeutic use
-
Injections, Jet
-
Insulin / administration & dosage*
-
Insulin / adverse effects
-
Insulin / economics
-
Insulin / therapeutic use
-
Insulin Infusion Systems* / adverse effects
-
Insulin Infusion Systems* / economics
-
Insulin Infusion Systems* / trends
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / economics
-
Recombinant Proteins / therapeutic use
Substances
-
Biosimilar Pharmaceuticals
-
Hypoglycemic Agents
-
Insulin
-
Recombinant Proteins